Evotec's insights into GPCRs and waveRAPID technology reveal new opportunities in drug discovery, focusing on orphan ...

Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei ... well as where he thinks AI’s use in drug discovery and development might lead the industry.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

“Septerna has demonstrated strong capabilities in GPCR drug discovery ... The company is focused on the discovery and development of a pipeline of oral small molecules for multiple therapeutic ...